November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

FDA Declines Approval for Lung Cancer Drug Ivonescimab

🧠 Mind & Mental Health 1 min read 👁 7

Regulatory authorities have turned down the lung cancer therapy ivonescimab, developed by Summit Therapeutics and Akeso, citing a lack of demonstrated overall survival benefit.

FDA Declines Approval for Lung Cancer Drug Ivonescimab🧠Mind & Mental Health

Photo: statnews.com

Key points

  • The FDA rejected the lung cancer treatment ivonescimab.
  • Developers Summit Therapeutics and Akeso were notified via a formal letter.
  • Regulators cited a lack of proven overall survival benefit despite delayed disease progression.

Regulatory Decision on Ivonescimab

The U.S. Food and Drug Administration has issued a complete response letter declining approval for ivonescimab, a targeted treatment for a specific form of lung cancer developed jointly by U.S.-based Summit Therapeutics and Chinese pharmaceutical firm Akeso. According to the companies, regulatory reviewers determined that although the therapy demonstrated an ability to slow the progression of the disease, it failed to show that patients lived longer as a result.

Agency reviewers concluded that this absence of an overall survival benefit meant the medication did not maintain a favorable benefit-risk profile required for clearance. Summit Therapeutics manages the development and commercialization rights for the drug outside of China, and company representatives noted that the regulatory hurdle, while significant, was not entirely unexpected.

What to know: Regulatory decisions rely heavily on demonstrable extensions in patient survival rates. Readers navigating oncology care options should consult qualified medical professionals for personalized guidance.

Source statnews.com — statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatme… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.